International Society for the Study of Women's Sexual Health

Flibanserin recommended for approval by the FDA Advisory Committee Panel

Dear ISSWSH members,
It is with great excitement that I share the announcement that flibanserin, a drug for hypoactive sexual desire disorder (HSDD) developed by Sprout Pharmaceuticals, was recommended for approval by the FDA Advisory Committee Panel on June 4, 2015.

This event opens the door for the first treatment for women suffering from HSDD, but more importantly sends the message that the FDA is now willing to entertain new drug applications from other companies. We are optimistic that this occurrence will instigate more research and eventually other therapeutic options. We also offer deep gratitude to many of our members who played a key role in this decision by voting as members of the FDA Advisory Panel, speaking as presenters on behalf of the sponsor, providing testimony during the Open Public Hearing, and caring for patients who also spoke at the Hearing.  

As a multidisciplinary, scientific organization dedicated to research, clinical practice, and education, we are poised to develop and disseminate clinical practice guidelines regarding screening, diagnosis, and management strategies. Through our robust infrastructure of educational programs, we will ensure appropriate, safe, and selective treatment of HSDD with flibanserin when final approval comes.

Most sincerely,
Sharon J. Parish, MD, IF
ISSWSH President, 2014-2016

Save the Date

ISSWSH Fall Course 2019
November 14-16, 2019   0 days left
DoubleTree Hilton Hotel, Scottsdale, AZ - USA
Read more...

ISSWSH Annual Meeting 2020
March 5-8, 2020   112 days left
Renaissance Orlando at Seaworld, Orlando, FL, USA

ISSWSH Sexual Pain Course 2020
April 17-18, 2020 112 days left
Georgetown University Medical Center, Medical and Dental Building, Washington, DC, USA

ISSWSH Annual Meeting 2021
March 4-7, 2021   476 days left
Renaissance Dallas Hotel, Dallas, TX, USA

Latest Tweets

@StephFaubionMD and Management of Genitourinary Syndrome of Menopause in Female Cancer Patients: A Focus on Vaginal… https://t.co/ydvLaADZ2V ISSWSH
Retrospective chart review shows that patients with vulvodynia do NOT have higher rates of infertility treatment co… https://t.co/Ri5nVIzNL9 ISSWSH
One of the biggest warnings when using Addyi for female HSDD is hypotension and syncope with alcohol consumption.… https://t.co/UNxsJIzI1J ISSWSH

Contact Details

ISSWSH Executive Office
14305 Southcross Dr
Suite 100
Burnsville, MN 55306
USA

Phone: +1 (952) 683 9025
Fax: +1 (952) 314 8212
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Follow us on Twitter!